Perspectives on Signal Intelligence, behavior-based coaching, and building judgment through practice — from the team behind ReflectivAI.
At a 2026 industry conference, MHRA's David Brown delivered an unambiguous message that AI governance is a present, not future, regulatory requirement, and that inspectors are already asking about it.
Regulators increasingly expect organizations to prove traceability, accountability, and governance over AI agents running in live production environments, not just rely on surface-level guardrails.
Deloitte's global survey found a staggering 54-point gap: 82% of life sciences executives are satisfied with their current customer engagement strategies, while only 28% of HCPs feel those…
A Deloitte global survey of over 190 HCPs and 50 pharmaceutical executives from the top 25 pharma firms found 82% of life sciences executives satisfied with their current customer engagement…
Industry analysis frames the core buyer test as answer consistency, not raw capability, positioning governed, deterministic autonomy as the credible pattern for pharma commercial AI agents versus…
97% of pharma digital outreach to HCPs goes unanswered, while 82% of pharma executives believe their efforts are effective, but only 28% of HCPs agree.
The core statistic: HCP access dropped from 60% to 45% in 18 months, with half of accessible HCPs restricting engagement to three or fewer companies.
Veeva's Pulse Field Trends Report data shows U.S. HCP access fell from 60% in 2022 to 45% in 2024, reverting to pre-pandemic levels.
A Deloitte global survey found that 82% of life sciences executives are satisfied with their current customer engagement strategies, while only 28% of HCPs feel these strategies meet their needs…
MIT's widely-cited 2025 report found that 95% of enterprise generative AI pilots fail to deliver measurable financial return, and only about 5% reach scaled production.
MIT's NANDA initiative found that 95% of enterprise generative AI pilots fail to deliver measurable financial return, while only about 5% successfully scale to deliver rapid revenue impact.
Field rep access to HCPs has fallen to pre-pandemic levels: only 45% are accessible to biopharmas, down from 60% eighteen months earlier, and half of those restrict engagement to digital channels.
Pharma's agentic AI pilots keep working. Scaling them keeps stalling. The real bottleneck isn't data quality — it's who decides which HCP-facing moments belong to a machine and which don't.
Two forces, shrinking physician access and AI automation, are turning the live clinical conversation into the highest-leverage and hardest-to-scale asset in life sciences commercial. A behavioral framework for measuring and scaling judgment.
There is a coaching perception gap: 90% of leaders say they coach monthly, but 38% of reps say they rarely or never receive it.
AI sales coaches are being trusted to judge how reps perform — but they invent objections that were never raised, stay confident when they're wrong, and penalize the wrong things. Here is the credibility standard that separates real coaching signal from algorithmic noise.
Signal Intelligence is the ability to notice, interpret, and respond to the observable signals in a high-stakes conversation. Here is what it means, why it is behavior-based, and how commercial teams put it into practice.
Numeric scorecards feel objective but quietly break coaching. Here is the case for behavior-based feedback — specific, in the moment, and always human-led — and how it changes what managers and reps do differently.
The first time a rep handles a hard HCP objection should not be in front of the HCP. Here is why deliberate rehearsal against adaptive AI personas builds judgment and fluency that role-play scripts never could.